Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Opinion Statement: The therapeutic landscape of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) has evolved significantly in recent years. Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine k...
| Publicado en: | Current Treatment Options in Oncology Vol. 18; no. 3; pp. 1 - 15 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Mar2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122726403&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 122726403 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Mar2017 vid: 18 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 122726403 122726403 NLM28286921 122726403 10.1007/s11864-017-0461-5 NLM28286921 122726403 ppf: 1 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. aug: au: Cives, Mauro Strosberg, Jonathan affil: Department of Gastrointestinal Oncology , H. Lee Moffitt Cancer Center and Research Institute , 12902 Magnolia Drive Tampa 33612 USA sug: subj: Gastrointestinal Neoplasms Therapy Neuroendocrine Tumors Therapy Neuroendocrine Tumors Pathology Gastrointestinal Neoplasms Pathology Antineoplastic Agents Therapeutic Use Neoplasm Metastasis Clinical Trials Human Stomach Neoplasms Pathology Pancreatic Neoplasms Therapy Combined Modality Therapy Antineoplastic Agents Pharmacodynamics Drug Therapy Pancreatic Neoplasms Metabolism Neuroendocrine Tumors Metabolism Pancreatic Neoplasms Pathology Algorithms Intestinal Neoplasms Therapy Gastrointestinal Neoplasms Metabolism Intestinal Neoplasms Pathology Neoplasm Staging Stomach Neoplasms Therapy Antineoplastic Agents, Combined Adverse Effects Intestinal Neoplasms Metabolism Stomach Neoplasms Metabolism Treatment Outcomes Antineoplastic Agents, Combined Therapeutic Use ab: Opinion Statement: The therapeutic landscape of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) has evolved significantly in recent years. Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine kinase inhibitor sunitinib. Although high-quality data from phase III trials are lacking, cytotoxic agents are commonly used for the treatment of poorly differentiated neuroendocrine carcinomas and well-differentiated NETs originating in the pancreas. Hepatic-directed therapies are recommended for patients with slow-growing, liver-predominant disease but have never been compared to systemic agents. Telotristat ethyl, a novel serotonin synthesis inhibitor, has recently demonstrated efficacy in palliating diarrhea in patients with poorly controlled carcinoid syndrome. In the absence of definite predictive biomarkers, therapeutic decisions in most cases rely on clinical and pathological criteria. However, navigating the current therapeutic algorithm may be challenging, and future trials need to address several important questions: what is the best sequence of treatment? Is there a role for combination therapies in GEP-NETs? Are neoadjuvant, adjuvant, or maintenance strategies safe and effective? Do all NET patients require active treatment? What new molecular targets can be clinically exploited? A tight integration between basic and clinical research is needed to further advance the field of NETs. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|